Filing Flows › Comparisons › RGBP vs AVTX
Regen BioPharma vs Avalo Therapeutics: RGBP and AVTX compared
Regen BioPharma is the larger company: $59K of revenue in its latest quarter (Q3 FY26) against $59K for Avalo Therapeutics (Q4 2025). Regen BioPharma is growing faster (0% against -69% a year earlier).
Where the money goes: RGBP and AVTX
Regen BioPharma (RGBP) · Q3 FY26
Regen BioPharma, Q3 FY26: revenue $59K (0% year over year), operating margin 41.5%, net loss $638K, operating cash flow −$24K. The chart follows the revenue to costs, profit and cash.
Avalo Therapeutics (AVTX) · Q4 2025
Avalo Therapeutics, Q4 2025: revenue $59K (-69% year over year), net loss $13.7M, operating cash flow −$14.2M. The chart follows the revenue to costs, profit and cash.
| Regen BioPharma (RGBP) | Avalo Therapeutics (AVTX) | |
|---|---|---|
| Latest quarter | Q3 FY26 | Q4 2025 |
| Revenue | $59K | $59K |
| Revenue growth, Y/Y | 0% | -69% |
| Operating margin | 41.5% | n/m |
| Net earnings | −$638K | −$13.7M |
| Operating cash flow | −$24K | −$14.2M |
| Market value | — | $595M |
| Analysts’ mean target | — | $36.60 |
Questions
Which is bigger, Regen BioPharma or Avalo Therapeutics?
Regen BioPharma is the larger company: $59K of revenue in its latest quarter (Q3 FY26) against $59K for Avalo Therapeutics (Q4 2025).
Is Regen BioPharma or Avalo Therapeutics growing faster?
Regen BioPharma is growing faster (0% against -69% a year earlier).
More: Regen BioPharma earnings · how Regen BioPharma makes money · Avalo Therapeutics earnings · how Avalo Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 17, 2026; 10-K filed Mar 23, 2026). Fiscal quarters can end on different dates. Not investment advice.